Research programme: oncology therapeutics - Neovia OncologyAlternative Names: Neo 2; Neo 3; Neo 4; Neo AD1; NEV 2; NEV 3; NEV 4; NEV AD1
Latest Information Update: 03 Jun 2015
At a glance
- Originator Neovia Oncology
- Class Antineoplastics; Camptothecins; Colchicum alkaloids; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; Tubulin polymerisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 31 May 2015 Preclinical trials in Cancer in USA (unspecified route)